United States Drug Patent 9,814,690: Claims, Scope, Expiration, Orange Book Status, and Competitive Landscape

U.S. Patent No. 9,814,690 protects a narrow topical acne formulation combining 0.3% adapalene, 2.5% dispersed benzoyl peroxide, and 2% to 5% of the acrylamide sodium acryloyldimethyltaurate/isohexadecane/polysorbate 80 gelling system. The patent also covers treatment of common acne with that formulation and a packaged product containing it. The claims closely track Galderma’s Epiduo Forte product.

The core commercial risk is formulation overlap. A competing product can avoid literal infringement by changing the active concentrations, using a different gelling system, altering the physical form of benzoyl peroxide, or designing around the claimed product configuration. The patent does not broadly cover every adapalene and benzoyl peroxide product.

What does U.S. Patent 9,814,690 protect?

U.S. Patent 9,814,690 contains three principal claim categories:

Claim category	Claims	Protected subject matter
Composition	1-2	A physiologically acceptable aqueous gel containing 0.3% adapalene, 2.5% dispersed benzoyl peroxide, and 2% to 5% of the specified gelling agent
Method of treatment	3-4	Treating common acne by administering the claimed aqueous gel
Packaged product	5-6	A container holding the claimed acne gel

The narrower dependent claims reduce the gelling-agent range from 2% to 5% to 3.5% to 4%.

The patent is assigned to the Galderma group and is associated with the fixed-dose adapalene/benzoyl peroxide product Epiduo Forte, which contains adapalene 0.3% and benzoyl peroxide 2.5% [1][2].

What ingredients and concentrations are required by the patent claims?

Claim 1 requires all of the following:

An aqueous gel composition.
A physiologically acceptable formulation.
Anti-acne actives consisting of:
- 0.3% adapalene and/or a pharmaceutically acceptable salt; and
- 2.5% dispersed benzoyl peroxide.
A gelling agent consisting of the named acrylamide sodium acryloyldimethyltaurate/isohexadecane/polysorbate 80 system.
The gelling agent present at 2% to 5% by weight of the total composition.

The gelling system is commonly associated with the commercial ingredient marketed as Sepineo P 600. The claim is directed to the complete pre-mixed polymer, hydrocarbon, and surfactant system rather than merely to one component of that system.

How should the “and/or” language be read?

The active limitation requires 0.3% adapalene or an acceptable salt of adapalene, or both, together with 2.5% dispersed benzoyl peroxide. Because the claim separately requires benzoyl peroxide, a product containing only adapalene without benzoyl peroxide would not satisfy the literal wording of claim 1.

The phrase “and/or” creates drafting breadth for adapalene and its salt but does not remove the requirement for the claimed concentration of benzoyl peroxide.

What does “consisting of” limit?

The phrase “anti-acne actives consisting of” is narrower than “comprising.” It limits the anti-acne active portion to the specified adapalene component and benzoyl peroxide. A competing product adding another pharmacologically active acne ingredient, such as clindamycin, may create a non-infringement argument under the claim’s active-ingredient limitation.

The overall formulation remains open-ended because the claim uses “comprising” before the composition elements. Additional inactive excipients, stabilizers, humectants, preservatives, pH modifiers, and processing aids can therefore be present.

How narrow is the formulation claim?

The formulation claim is narrow in concentration and excipient selection but broad in the identity of unclaimed inactive ingredients.

A product would generally require close analysis against the following claim elements:

Element	Claim requirement	Design-around significance
Dosage form	Physiologically acceptable aqueous gel	A cream, lotion, anhydrous gel, foam, or non-aqueous system may avoid literal infringement
Adapalene	0.3%	A materially different concentration may avoid literal infringement
Benzoyl peroxide	2.5%, dispersed	A different concentration or physical presentation may create separation
Gelling system	Acrylamide sodium acryloyldimethyltaurate/isohexadecane/polysorbate 80	A different polymer or rheology modifier is the clearest formulation design-around
Gelling-agent amount	2% to 5%	Less than 2% or more than 5% may fall outside claim 1
Narrow range	3.5% to 4%	Claims 2, 4, and 6 impose the narrower range
Product format	Container containing the claimed gel	Product claims are directed to the combination of container and formulation

The use of “comprising” means that a product does not avoid the claim merely because it contains additional inactive ingredients. It must omit or materially alter a required limitation.

What do claims 2, 4, and 6 add?

Claims 2, 4, and 6 cover the narrower gelling-agent concentration of 3.5% to 4%.

Dependent claim	Parent claim	Narrowing feature
2	1	Gelling agent at 3.5% to 4%
4	3	Same narrower gelling-agent range in the treatment method
6	5	Same narrower range in the packaged product

These claims can remain important even if a challenger establishes that the broader 2% to 5% range lacks patentable distinction. A formulation within 3.5% to 4% would need to address both the broader composition claim and the narrower dependent claim.

What is the scope of the method-of-treatment claims?

Claims 3 and 4 cover treating common acne by administering the claimed composition to a subject in need thereof.

The method claims create a separate infringement theory from the composition claims. They are particularly relevant to:

Prescription drug labeling;
Instructions for use;
ANDA products with an acne indication;
Physician and pharmacy distribution;
Induced-infringement allegations based on a generic label.

A generic product may attempt a section viii or “skinny label” strategy if it can omit the patented method from its proposed labeling. That strategy is less effective where the product’s only practical or approved use is the patented acne treatment and the formulation itself remains within the composition claims.

What does the container claim protect?

Claims 5 and 6 cover a product consisting of:

A container; and
The claimed aqueous acne gel contained in that container.

The product claims do not appear to require a particular tube, pump, bottle, label, closure, or dispensing mechanism. The container limitation is therefore relatively broad. A tube, pump dispenser, jar, or other conventional container could potentially satisfy the limitation if it contains the claimed formulation.

These claims are less useful against bulk formulation manufacture before packaging unless the accused product has entered the claimed product configuration. They can be relevant to finished-goods sales, importation, distribution, and commercial packaging.

When does U.S. Patent 9,814,690 lose exclusivity?

The patent issued on November 14, 2017 [1]. Its anticipated base patent-term expiration is in September 2032, subject to the official USPTO patent-term calculation, any patent-term adjustment, and any applicable statutory extension.

Milestone	Date or status
Patent issued	November 14, 2017
Anticipated base expiration	September 2032
Patent-term adjustment	Must be confirmed from the USPTO patent record
Pediatric extension	No extension should be assumed without an FDA and USPTO record showing that it was granted
Regulatory exclusivity	Separate from patent term and governed by the NDA approval history

The patent’s effective loss of market protection may occur before formal expiration if a generic applicant prevails in Paragraph IV litigation, obtains a favorable judgment of non-infringement or invalidity, or launches at risk.

What is the Orange Book status of the patent?

U.S. Patent 9,814,690 is associated with Galderma’s Epiduo Forte 0.3%/2.5% topical gel and should be evaluated through the FDA Orange Book record for the relevant NDA and strength [2].

Orange Book listing has practical consequences:

An ANDA applicant must address the listed patent.
A Paragraph IV certification can trigger notice and litigation.
A timely patent-infringement action can impose a statutory 30-month stay of ANDA approval.
The listing does not establish validity or infringement.
The patent must be evaluated with the listed use code and product scope, not solely by its presence in the Orange Book.

Epiduo Forte is a drug product, not a biologic. Biosimilar procedures under the Public Health Service Act do not apply. The relevant competitive pathway is an ANDA for a generic drug, not a biosimilar application.

What FDA exclusivity applies to Epiduo Forte?

Epiduo Forte was approved by FDA as a prescription topical acne product containing adapalene 0.3% and benzoyl peroxide 2.5% [3].

FDA regulatory exclusivity and patent protection are separate:

Protection	Function
New-drug exclusivity	Restricts certain FDA approvals for a defined period
Orange Book patent	Requires patent certification by an ANDA applicant
Patent litigation stay	Can delay ANDA approval after qualifying Paragraph IV litigation
Patent expiration	Ends the statutory exclusionary right, subject to term adjustments
Label exclusivity	May protect a specific indication or labeling element

The commercial barrier for a generic competitor is therefore a combination of formulation similarity, ANDA requirements, patent certification, potential litigation, and manufacturing validation.

Which companies are challenging U.S. Patent 9,814,690?

The claim text alone does not establish the identity or status of any Paragraph IV challenger. A reliable challenge analysis must distinguish:

An ANDA filing;
A Paragraph IV notice letter;
A filed district-court action;
An inter partes review petition;
A settlement agreement; and
A commercial launch.

No conclusion about a company’s challenge should be drawn from a generic product application, a patent citation, or a public patent-family record alone.

For this patent, the likely challenge theories would include:

Anticipation: A prior-art acne gel disclosing the claimed concentrations, dispersed benzoyl peroxide, and the same gelling system.
Obviousness: Combining known adapalene/benzoyl peroxide therapy with a known aqueous-gel vehicle and selecting the claimed concentration range.
Indefiniteness: Attacking terms such as “physiologically acceptable,” “dispersed,” “common acne,” or the chemical naming of the gelling agent.
Written description or enablement: Arguing that the full 2% to 5% range or all covered formulation variants are not adequately supported.
Non-infringement: Using a different polymer system, different active concentration, or different dosage form.

How strong is the patent estate for Epiduo Forte?

The strength of the estate depends on the difference between the narrow commercial formulation and the broader prior art.

Strengths

The claims identify a precise commercial combination: 0.3% adapalene and 2.5% benzoyl peroxide.
The claims require a specific gelling-agent system and concentration range.
The patent includes composition, method, and packaged-product claim types.
The 3.5% to 4% dependent range provides a narrower fallback position.
The product claims may support infringement theories against finished generic products, not only bulk formulations.

Vulnerabilities

Adapalene and benzoyl peroxide were known acne actives before this patent.
Aqueous topical gels and polymeric gelling systems were established formulation technologies.
The patent’s inventive step may depend heavily on the selected vehicle, concentration range, dispersion, stability, and formulation performance.
The claims do not cover every adapalene/benzoyl peroxide concentration.
A competitor using a different gelling agent may have a credible design-around.
Method claims may be vulnerable to skinny-label strategies if the formulation claims are also avoided.

The commercial patent position is stronger against a close copy of Epiduo Forte than against a materially different adapalene/benzoyl peroxide product.

What formulation patents could compete with this patent?

The relevant patent landscape includes several overlapping but distinct technology groups.

Adapalene patents

Earlier patents cover adapalene itself, its dermatological use, and formulations containing adapalene. Those rights are generally distinct from the specific 0.3% adapalene/2.5% benzoyl peroxide formulation claimed in U.S. 9,814,690.

Benzoyl peroxide formulation patents

Benzoyl peroxide patents often focus on:

Particle size;
Stabilization;
Suspension and dispersion;
Controlled release;
Combination with retinoids;
Reduced irritation; and
Packaging and oxygen or moisture control.

A generic product can avoid U.S. 9,814,690 while still encountering separate rights directed to benzoyl peroxide processing or stabilization.

Combination acne products

Relevant competing products include:

Product	Active combination	Competitive relevance
Epiduo	Adapalene 0.1% and benzoyl peroxide 2.5%	Lower-adapalene-strength predecessor
Epiduo Forte	Adapalene 0.3% and benzoyl peroxide 2.5%	Product most closely aligned with the patent
Tazarotene products	Tazarotene	Retinoid alternative
Twyneo	Tretinoin and benzoyl peroxide	Fixed-dose retinoid/BPO competitor
Cabtreo	Trifarotene, clindamycin, and benzoyl peroxide	Triple-active topical competitor
Clindamycin/BPO products	Antibiotic and benzoyl peroxide	Alternative combination therapy

These products do not necessarily practice the claims of U.S. 9,814,690 because they use different retinoids, active concentrations, or formulation systems.

What generic launch scenarios exist?

Scenario 1: Close-copy ANDA

A generic applicant matches 0.3% adapalene, 2.5% benzoyl peroxide, and the claimed gel system. This presents the highest infringement exposure. The likely pathway is Paragraph IV certification followed by patent litigation.

Scenario 2: Different gelling system

The applicant uses a carbomer, cellulose derivative, poloxamer, or another polymer system. This is the most direct formulation design-around, but the product must still satisfy FDA sameness and performance requirements for the proposed reference product.

Scenario 3: Different adapalene concentration

A product containing 0.1% adapalene and 2.5% benzoyl peroxide may compete with Epiduo rather than Epiduo Forte. It would generally fall outside the literal 0.3% adapalene limitation.

Scenario 4: Different dosage form

A cream, lotion, foam, suspension, or anhydrous system may avoid the aqueous-gel limitation. Regulatory comparability and dermatological performance would determine whether the alternative is commercially viable.

Scenario 5: At-risk launch

A generic applicant may launch before patent expiry after receiving a favorable court ruling or accepting litigation risk. This can produce damages exposure, injunction risk, and rapid price erosion.

What manufacturing and geographic barriers matter?

The patent is a U.S. right. It does not directly block manufacture or sale outside the United States. Geographic risk depends on:

National patent-family members;
Local patent term;
Regulatory approval;
Importation into the United States;
Contract manufacturing location;
Export controls and supply-chain routing.

Manufacturing barriers may arise from the need to:

Disperse benzoyl peroxide uniformly;
Maintain adapalene stability;
Control viscosity across the claimed gelling-agent range;
Prevent phase separation;
Validate microbial control;
Demonstrate tube or pump compatibility; and
Establish equivalence to the reference product.

A competitor can avoid the patent and still face substantial CMC and ANDA development costs.

Are licensing deals or settlement agreements known?

The patent itself does not establish a license, covenant not to sue, authorized-generic arrangement, or patent settlement. Any such agreement would require review of SEC filings, FTC materials, court dockets, or FDA-related commercial records.

For valuation purposes, a settlement may allow a generic launch before the nominal patent expiration date. The launch date in a settlement can therefore be more commercially important than the September 2032 statutory expiration.

Key Takeaways

U.S. Patent 9,814,690 is directed to a specific aqueous gel for common acne.
The key formulation is 0.3% adapalene, 2.5% dispersed benzoyl peroxide, and 2% to 5% of a specified gelling system.
Claims 2, 4, and 6 narrow the gelling-agent concentration to 3.5% to 4%.
The patent covers composition, treatment method, and packaged-product configurations.
The claims are not broad coverage of all adapalene/benzoyl peroxide products.
Epiduo Forte is the principal commercial product associated with the patent.
The anticipated patent term extends into September 2032, subject to official term adjustments.
The patent is relevant to ANDA Paragraph IV analysis, but biosimilar procedures do not apply.
The strongest design-around is a different gelling system combined with a materially different formulation architecture.
The largest generic-launch risk is a close copy of Epiduo Forte using the same active concentrations and vehicle.

FAQs About U.S. Patent 9,814,690

Does U.S. Patent 9,814,690 cover Epiduo?

It is primarily associated with Epiduo Forte, which contains 0.3% adapalene and 2.5% benzoyl peroxide. The original Epiduo product contains 0.1% adapalene and is not necessarily within the literal concentration limitation.

Can a generic use adapalene 0.3% and benzoyl peroxide 2.5%?

Yes, but it must avoid the patent claims or obtain a license. Using the same concentrations alone does not establish infringement, but using the same aqueous gel and specified gelling system creates substantial risk.

Does the patent cover benzoyl peroxide creams?

Not as written. The claims require a physiologically acceptable aqueous gel. A cream may avoid literal infringement, although the doctrine of equivalents and other patents must be considered.

Is a generic version subject to biosimilar litigation?

No. Epiduo Forte is a conventional small-molecule topical drug. A generic applicant would use the ANDA pathway, not the biosimilar pathway.

Can changing Sepineo P 600 avoid the patent?

A different gelling system may avoid literal infringement if the replacement does not contain the claimed acrylamide sodium acryloyldimethyltaurate/isohexadecane/polysorbate 80 system. The full formulation and any doctrine-of-equivalents theory would still require analysis.

References

United States Patent and Trademark Office. (2017). U.S. Patent No. 9,814,690, aqueous gel composition for treatment of common acne.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2015). Epiduo Forte prescribing information. Galderma Laboratories, L.P.
United States Code, 35 U.S.C. §§ 154, 271, 282, 355.
United States Code, 21 U.S.C. § 355(j).

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	01 16747	Dec 21, 2001

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1458369	⤷ Start Trial	CA 2008 00029	Denmark	⤷ Start Trial
European Patent Office	1458369	⤷ Start Trial	08C0024	France	⤷ Start Trial
European Patent Office	1458369	⤷ Start Trial	SPC/GB10/005	United Kingdom	⤷ Start Trial
European Patent Office	1458369	⤷ Start Trial	C01458369/01	Switzerland	⤷ Start Trial
European Patent Office	1458369	⤷ Start Trial	380	Finland	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 9,814,690